Safe and active advanced T cell therapies

We apply our broad array of T cell programming technologies and capabilities to engineer precisely targeted controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eradicate these cancer cells.

CAR T cell therapies

We use Chimeric Antigen Receptors (CARs) to reprogram our T cell product candidates. These receptors combine the tumor recognition domain of an antibody with the activation and costimulatory domains from the t cell receptor to rearm a patient’s T cells to recognize and kill their cancer cells.

Find out more

Pipeline Products

Our next generation, programmed T cell therapies in development.

Learn more

Advanced cell programming technology

Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products.

Read more


We manufacture our product candidates and commercial supply in the UK.

Learn more

Latest Abstracts & Publications

See all
Nature Medicine
July 06 2023

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

Cancer Immunology Research
June 26 2023

Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine Receptors

Molecular Therapy Nucleic Acids
April 25 2023

Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy